BioWorld at 35: a legacy of trusted journalism, a future of innovation

Thirty-five years is a milestone worth pausing for. In industries as fast-moving as biopharma and medtech, where breakthroughs, challenges and discoveries reshape the landscape daily, few constants remain. BioWorld is one of them.

Since 1990, our mission has been clear: to cut through the noise with accuracy, clarity and context. What began as a short-lived print magazine quickly transformed to fax and then online distribution in 1991, making BioWorld one of the first digital-first news services in life sciences. That agility, and our commitment to meeting readers where they are, have defined us ever since. By 1994, we expanded into medtech with BioWorld MedTech, and later, in 2018, into discovery and preclinical coverage with BioWorld Science. Each step reflected the same principle. Anticipate our readers’ needs and deliver the right insights when they need them most.

Today, the media landscape looks completely different. Consolidation, misinformation and declining trust have challenged even the most established outlets. A 2024 survey shows over 40% of journalists cited maintaining credibility as their biggest hurdle. Against this backdrop, BioWorld has held firm. BioWorld has earned 77 awards since 1998, including seven recent honors from Apex — among them a Grand Award for a special series on pioneering efforts to develop a universal HIV cure — recognizing excellence in journalism, analysis and digital publishing. Our award-winning journalists, backed by Clarivate data and expertise, provide the kind of timely, data-driven reporting that industry leaders, investors and policymakers depend on. From licensing deals and clinical trial results to regulatory shifts and M&A, we aim to not only report the news but also show why it matters.

And it does matter. BioWorld is regularly cited in investor calls, regulatory filings and industry policy debates. Our readers include executives at major pharmaceutical and medtech companies, top-tier investors, regulators and scientists. As Bradley Burnam, CEO of Turn Therapeutics, shared: “Being featured by BioWorld means our work is being recognized as meaningful and credible by some of the most influential voices in the space.”

That credibility is not accidental. It is earned daily, story by story. As David Schull, President of Russo Partners, put it: “When we work with BioWorld staffers, we know the commitment is to get the facts right, no matter the news. Balanced. Fair.”

So as we celebrate 35 years, this is more than an anniversary. We are dedicated to our mission of being an independent, trusted partner to our readers, guiding them through discovery, development and commercialization with clarity and confidence.

As the next chapter brings even faster innovation in science and technology, our role is to provide clarity and insight every step of the way. To see what matters, explain why it matters, and always put our readers first.

Here’s to the past 35 years — and to the future of life sciences journalism.

To celebrate, start your free trial today.

content_copy Copy link Copied